Correlation Between GM and Protalix Biotherapeutics
Can any of the company-specific risk be diversified away by investing in both GM and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining GM and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between General Motors and Protalix Biotherapeutics, you can compare the effects of market volatilities on GM and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in GM with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of GM and Protalix Biotherapeutics.
Diversification Opportunities for GM and Protalix Biotherapeutics
-0.5 | Correlation Coefficient |
Very good diversification
The 3 months correlation between GM and Protalix is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding General Motors and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and GM is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on General Motors are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of GM i.e., GM and Protalix Biotherapeutics go up and down completely randomly.
Pair Corralation between GM and Protalix Biotherapeutics
Allowing for the 90-day total investment horizon General Motors is expected to under-perform the Protalix Biotherapeutics. But the stock apears to be less risky and, when comparing its historical volatility, General Motors is 1.38 times less risky than Protalix Biotherapeutics. The stock trades about -0.03 of its potential returns per unit of risk. The Protalix Biotherapeutics is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest 183.00 in Protalix Biotherapeutics on December 27, 2024 and sell it today you would earn a total of 65.00 from holding Protalix Biotherapeutics or generate 35.52% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
General Motors vs. Protalix Biotherapeutics
Performance |
Timeline |
General Motors |
Protalix Biotherapeutics |
GM and Protalix Biotherapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with GM and Protalix Biotherapeutics
The main advantage of trading using opposite GM and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if GM position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.The idea behind General Motors and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Complementary Tools
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Transaction History View history of all your transactions and understand their impact on performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Fundamental Analysis View fundamental data based on most recent published financial statements |